This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ICAD Reports Significantly Improved Medicare Payment For Intraoperative Radiation Therapy

Stocks in this article: ICAD

iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced imaging and radiation therapy for the early identification and treatment of cancer, today announced the U.S. Centers for Medicare & Medicaid Services (CMS) has issued an improved payment policy for Intraoperative Radiation Therapy (IORT), which is delivered by the Company’s Xoft® Axxent® Electronic Brachytherapy System®. In the 2013 Final Rule issued November 1, 2012, CMS unpackaged the IORT payment codes and assigned a distinct payment value for IORT treatment delivery. CMS assigned IORT treatment delivery to the same ambulatory payment classification as Stereotactic Radiosurgery, MRgFUS and MEG, Level 1.

The payment value for IORT treatment delivery in the Final Rule is more than twice the value included in the Proposed Rule released by CMS in July 2012. The 2013 Final Rule payment codes will take effect on January 1, 2013.

“The decision by CMS to unpackage IORT payments and increase reimbursement rates underscores the cost-effectiveness of this potentially life-saving radiation therapy option that can dramatically reduce treatment times, while providing more convenient and aesthetically desirable outcomes for women with early-stage breast cancer,” said Ken Ferry, President and CEO of iCAD. “We believe this ruling will provide greater access to IORT and accelerate the growing adoption of our technology by radiation oncologists and breast surgeons nationwide. It is noteworthy that IORT reimbursement was substantially improved in light of the overall streamlining of payments for radiation oncology services.”

About the Xoft System

iCAD’s Xoft System delivers IORT for breast cancer in a single, prescribed, targeted dose of isotope-free radiation directly to the tumor cavity during surgery. This minimizes radiation to healthy tissue and organs and eliminates the need for a shielded treatment environment. Typical radiation therapy methods for breast cancer include whole breast radiation, which involves daily treatments for five to seven weeks, and partial breast irradiation where 10 treatments are delivered over a period of five days.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,483.47 -195.23 -1.10%
S&P 500 2,040.87 -16.22 -0.79%
NASDAQ 4,717.0640 -54.6990 -1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs